Potential economic impact of increasing low dose aspirin usage on CVD in the US

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2365-2373

  Manson, Stephanie C ^a   Benedict, Agnes ^b   Pan, Feng ^a   Wittrup Jensen, Kim U ^c   Fendrick, A Mark ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b United BioSource Corporation   (Hungary)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Budget impact model; Cardiovascular disease; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; BUDGET; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST CONTROL; DRUG COST; ECONOMIC ASPECT; ECONOMIC EVALUATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; SECONDARY PREVENTION; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CHEMOPREVENTION; COST SAVINGS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PATIENT COMPLIANCE; PRIMARY PREVENTION; UNITED STATES; YOUNG ADULT;

EID: 77956781336     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.514481     Document Type: Article

References (50)

1. American Heart Association. Cardiovascular Disease Statistics, 2004. Available at: http://www.americanheart.org/presenter.jhtml? identifier¼4478 [Last accessed 18 December 2007]
2. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121:43-49
3. Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163: 2006-2010
4. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172
5. De Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95
6. Weinberger J. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drugs 2005;65:461-471
7. Montvale NJ. Drug Topics Red Book. Thomson Healthcare 2008
8. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480-486
9. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006;30:74-77
10. Pignone M, Anderson GK, Binns K, et al. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007;32:403-407
11. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372 (Pubitemid 43947981)
12. US Preventive Services Task Force (USPSTF). Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-160
13. Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-295
14. Annemans L, Lamotte M, Kubin M, et al. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. Int J Clin Pract 2006;60:1129-1137 (Pubitemid 44226755)
15. Lamotte M, Annemans L, Evers T, et al. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-169 (Pubitemid 43242197)
16. Tsutani K, Igarashi A, Fujikawa K, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 2007;46:157-162
17. Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
18. Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008; 117:2875-2883
19. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-686
20. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753
21. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-281
22. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-318
23. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-298
24. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
25. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2:e353
26. Global CardioAspirin Consumer Attitude and Usage Study 2006. Bayer Consumer Care Data on File
27. Saini SD, Schoenfeld P, Fendrick AM, et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008;168:1684-1690, discussion 91
28. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin-what's the risk? Aliment Pharmacol Ther 2006;24:897-908
29. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22
30. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57:326-332
31. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280:1930-1935
32. Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006;12:313-319
33. World Health Organization. Report on adherence to long-term therapies: evidence for action, 2003. Available at: www.adheris.com/art/whoreport.pdf [Last accessed 28 November 2007]
34. Portelli R, Lowe D, Irwin P, et al. Institutionalization after stroke. Clin Rehabil 2005;19:97-108
35. Jones A. The National Nursing Home Survey: 1999 summary. Vital Health Stat 2002;13:1-116
36. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373:1849-1860
37. Murphy M, Foster C, Sudlow C, et al. Cardiovascular disorders. Primary prevention. Clin Evid 2002:91-123
38. Carter AM, Catto AJ, Mansfield MW, et al. Predictive variables for mortality after acute ischemic stroke. Stroke 2007;38:1873-1880
39. Chang WC, Kaul P, Westerhout CM, et al. Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. Arch Intern Med 2003;163:2476-2484
40. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002;33:1034-1040
41. HCUP Data Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP), 1988-2001: A Federal-State-Industry Partnership in Health Data. Available at: www.ahrq.gov/data/hcup/hcup-pkt.htm [Last accessed 29 January 2008]
42. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med 2009;150: 396-404
43. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-271
44. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-679
45. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-1300
46. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736-743
47. El-Saed A, Kuller LH, Newman AB, et al. Geographic variations in stroke incidence and mortality among older populations in four US communities. Stroke 2006;37:1975-1979 (Pubitemid 44309889)
48. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115: e69-171
49. Augustovski FA, Cantor SB, Thach CT, et al. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med 1998;13:824-835
50. National Center for Health Statistics. Preliminary data for 2005. Available at http://198.246.98.21/nchs/data/hestat/preliminarydeaths05-tables. pdf#A [Last accessed 8 February 2008]